Stocks · News reference
Goldman Sachs Initiates Coverage On Braveheart Bio with Buy Rating, Announces Price Target of $48
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Braveheart Bio, Inc. (BRVE)
Filed: 2026-09-08 AccNo: 0001628280-26-060904 Size: 367 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
This Airbnb Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst